Deliver Your News to the World

Boehringer Ingelheim now markets nutraceuticals in the USA


Company celebrates 10 years of the Animal Health Natural Care Center

13 January 2006, Ingelheim/Germany, Copenhagen/Denmark, 13 January 2006 – Boehringer Ingelheim’s Natural Care Center (NCC) announced today that it will also be marketing two of its recent nutraceutical products in the United States: Diaque®, an oral rehydration supplement for calves, and Bovikalc®, an oral calcium supplement for cows, are now available in the USA.

Boehringer Ingelheim’s Natural Care Center (NCC), based in Denmark, is the Boehringer Ingelheim Animal Health unit for global activities in the market segment of nutraceuticals and other natural care products for dogs, cats, horses and cattle. The key areas of NCC’s development and business activities include: animal mobility, digestion, metabolic disorders, skin diseases and the cardiovascular system.

With Diaque® and Bovikalc® in the US, and the established European product portfolio with Seraquin, Viacutan®, Canosan®, Canikur®, Pronutrin®, Equitop Myoplast® and Viatop® , NCC has a sound position for further growth.

NCC products offer a valuable choice to farmers and veterinarians who are looking for a natural means to support animal health. They also complement the pharmaceutical treatment concepts developed by the corporation.

“The NCC business segment of Boehringer Ingelheim Animal Health has achieved double digit annual sales growth rates in recent years.

The successful history of our NCC business in the last ten years has shown that there is a high demand for natural nutritional supplements which bring increased value in addition to prescribed pharmaceutical treatments, for all veterinarians and farmers,” explained Dr Joachim Hasenmaier, Head of Boehringer Ingelheim Animal Health.

Responsible for the development, in-licensing, manufacture and marketing of natural care products, the NCC benefits from the parent company’s development expertise and global distribution network. NCC focuses on fast time-to-market procedures, solid branding and profound technical service.

”We are committed to the further growth of this business segment and are constantly looking for new compounds and new partners and alliances in the nutraceutical market,” added Dr Hasenmaier.

Boehringer Ingelheim Animal Health belongs to the Boehringer Ingelheim group of companies. The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 144 affiliates in 45 countries and nearly 36,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2004, Boehringer Ingelheim posted net sales of 8.2 billion euro while spending nearly one fifth of net sales of its largest business segment Prescription Medicines on research and development.

The animal health business operates in more than 20 countries including the USA, Canada, France, Germany, UK, Italy, Spain, Mexico, the Nordic countries and Japan. Since 1955, Boehringer Ingelheim Animal Health has been contributing to an appropriate supply of safe, nutritious food while promoting the emotional and physical benefits arising from the human-animal bond.


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.